Engineering Anti-Tau Monoclonal Antibodies for Alzheimer’s Disease and Parkinsonian Tauopathies: A Biotechnological Perspective

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 16 | Issue : 01 | Page :
    By

    Kumar Monu,

  • Soumili Majumdar,

  • Zeya Fatima,

  • Harsh Pandey,

  1. Student, Department of P.G. Studies and Research in Biological Science, Rani Durgawati Vishwavidyalaya, Jabalpur, Madhya Pradesh, India
  2. Researcher, KIIT University, Bhubaneshwar, Odisha, India
  3. Student, Department of P.G. Studies and Research in Biological Science, Rani Durgawati Vishwavidyalaya, Jabalpur, Madhya Pradesh, India
  4. Student, Department of P.G. Studies and Research in Biological Science, Rani Durgawati Vishwavidyalaya, Jabalpur, Madhya Pradesh, India

Abstract

Neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease are characterized by progressive neuronal loss associated with abnormal protein aggregation. Among these, tauopathies are defined by the accumulation of hyperphosphorylated tau protein, which plays a central role in disease progression. Advances in biotechnology have enabled the development of anti-tau monoclonal antibodies (mAbs) as promising therapeutic agents aimed at neutralizing pathological tau species and inhibiting their propagation. This review provides a comprehensive analysis of the biotechnological strategies underlying antibody engineering, production platforms, mechanisms of action, and clinical translation. Despite promising preclinical outcomes, limitations such as poor blood–brain barrier penetration and insufficient clinical efficacy remain major challenges. Emerging approaches including bispecific antibodies, nanobodies, and gene therapy-based delivery systems are discussed as next-generation solutions. Anti-tau monoclonal antibodies (mAbs) represent a promising therapeutic approach for Alzheimer’s disease and Parkinson’s disease, targeting pathological tau to inhibit its spread and promote clearance. Advances in antibody engineering have improved specificity and safety; however, challenges such as limited blood–brain barrier penetration and tau heterogeneity hinder clinical success. Emerging strategies, including bispecific antibodies, nanobodies, and gene-based delivery systems, aim to enhance therapeutic efficacy. Overall, anti-tau mAbs hold significant potential as disease- modifying treatments in neurodegenerative disorders.

Keywords: Alzheimer’s disease, Parkinson’s disease, Neurodegenerative disorders, monoclonal antibodies, anti tau mAb, (HEK293), CHO, A affinity chromatography and size- exclusion chromatography, coupled with rigorous analytical characterization using techniques like HPLC and mass spectrometry

[This article belongs to Research and Reviews : A Journal of Biotechnology ]

How to cite this article:
Kumar Monu, Soumili Majumdar, Zeya Fatima, Harsh Pandey. Engineering Anti-Tau Monoclonal Antibodies for Alzheimer’s Disease and Parkinsonian Tauopathies: A Biotechnological Perspective. Research and Reviews : A Journal of Biotechnology. 2026; 16(01):-.
How to cite this URL:
Kumar Monu, Soumili Majumdar, Zeya Fatima, Harsh Pandey. Engineering Anti-Tau Monoclonal Antibodies for Alzheimer’s Disease and Parkinsonian Tauopathies: A Biotechnological Perspective. Research and Reviews : A Journal of Biotechnology. 2026; 16(01):-. Available from: https://journals.stmjournals.com/rrjobt/article=2026/view=239718


References

1. Avila J, Lucas JJ, Pérez M, Hernández F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84(2):361–384.

2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine. 2012 Aug 30;367(9):795-804.

3. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine. 2012 Aug 30;367(9):795-804.

4. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: Current status and prospects. Lancet Neurol. 2018.

5. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.

6. Öztürk MM, Emgård J, García-Revilla J, Fernández-Calle R, Yang Y, Deierborg T, Roos TT. The role of microglia in the prion-like transmission of protein aggregates in neurodegeneration. Brain Communications. 2025;7(2):fcaf087.

7. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol. 2012;12(5):615–622.

8. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535.

9. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology. 2018 Jul;14(7):399-415.

10. Cummings J, Lee G, Nahed P, Kambar ME, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2022;8(1):e12295.

11. Demlova R, Valík D, Obermannova R, Zdražilová-Dubská L. The safety of therapeutic monoclonal antibodies. Physiol Res. 2016;65(Suppl 4):S455–S462.

12. Ding C, Wu Y, Chen X, Chen Y, Wu Z, Lin Z, Kang D, Fang W, Chen F. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019. Frontiers in public health. 2022 Nov 29;10:952161.

13. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harbor perspectives in biology. 2017 Jul 1;9(7):a028035.

14. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11(3):155–159.

15. Ghasemi M, Brown RH Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8:a024125.

16. Goedert M. Tau protein and neurodegeneration. InSeminars in cell & developmental biology 2004 Feb 1 (Vol. 15, No. 1, pp. 45-49). Academic Press.

17. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–781.

18. Hansson O. Biomarkers for neurodegenerative diseases. Nature medicine. 2021 Jun;27(6):954-63.

19. Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MD, Montes-de-Oca-Luna R, Garcia-Garcia A, Rodriguez-Rocha H. Antioxidant therapeutics in Parkinson’s disease: current challenges and opportunities. Antioxidants. 2021 Mar 15;10(3):453.

20. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. Nat Rev Neurol. 2016;12(1):15–27.

21. Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: Focus on Alzheimer’s and Parkinson’s diseases. International journal of molecular sciences. 2021 Aug 23;22(16):9082.

22. Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Applied microbiology and biotechnology. 2016 Apr;100(8):3451-61.

23. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. nature. 1975 Aug 7;256(5517):495-7.

24. Kovacs GG. Concepts and classification of neurodegenerative diseases. InHandbook of clinical neurology 2018 Jan 1 (Vol. 145, pp. 301-307). Elsevier.

25. Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson’s disease: a 2021 update. Pharmaceuticals. 2021 Jul 25;14(8):717.

26. Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza R, Ngu H, Foreman O, Chan R. Antibody-mediated targeting of tau invivo does not require effector function and microglial engagement. Cell reports. 2016 Aug 9;16(6):1690-700.

27. Li D, Cho YK. High specificity of widely used phospho-tau antibodies validated using a quantitative whole-cell based assay. Journal of neurochemistry. 2019 Sep 4;152(1):122.

28. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. Journal of biomedical science. 2020 Jan 2;27(1):1.

29. Mandelkow EM, Mandelkow E. Tau in Alzheimer’s disease. Trends Cell Biol. 1998;8(11):425–427.

30. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor perspectives in medicine. 2012 Jul 1;2(7):a006247.

31. Novak P, et al. Tau-targeted immunotherapy: Clinical trials and future directions. J Prev Alzheimers Dis. 2018.

32. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21(6):394–402.

33. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal antibodies: past, present and future. Concepts and Principles of Pharmacology: 100 Years of the Handbook of Experimental Pharmacology. 2019 Dec 10:81-141.

34. Lopez CL, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, Thomas RG. The Alzheimer’s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2019 Jan 1;5:216-27.

35. Relkin DA, et al. Challenges in Alzheimer’s clinical trials. J Alzheimers Dis. 2021.

36. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO molecular medicine. 2016 Jun 1;8(6):595-608.

37. Shepard HM, Phillips GL, Thanos CD, Feldmann M. Developments in therapy with monoclonal antibodies. Clin Med (Lond). 2017;17(3):220–232.

38. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609–622.

39. Tiller KE, Tessier PM. Advances in antibody design. Annual review of biomedical engineering. 2015 Dec 7;17(1):191-216.

40. Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. Lewy bodies in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2006;65:387–395.

41. Uversky VN. Dancing Protein Clouds: Intrinsically Disordered Proteins in the Norm and Pathology, Part C. Academic Press; 2021 Oct 14.

42. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5–21.

43. World Health Organization. Neurological disorders: public health challenges. World Health Organization; 2006.

44. Alzheimer’s Association. Alzheimer’s disease facts and figures. 2023.McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, Wyse RK, Stott SR. Parkinson’s disease drug therapies in the clinical trial pipeline: 2023 update. Journal of Parkinson’s Disease. 2023 Jun 13;13(4):427-39.

45 Kopil CM, Asis A, Campbell C, Chowdhury S, Dexter DT, Fargo KN, Lee KK, Matthews H, Taylor A, Xiao Y, Stephenson D. A coalition to advance treatments for Parkinson’s disease, dementia with Lewy bodies, and related disorders. Journal of Parkinson’s Disease. 2024 Sep 3;14(6):1105-14.

46 “Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. Journal of Alzheimer’s Disease. 2008 Oct 7;15(2):157-68.”

47. Murphy K, Weaver C. Janeway’s Immunobiology. 9th ed. Garland Science; 2017.

48 Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Elsevier; 2021.

49 Silverstein AM. A history of immunology. Academic Press; 2009 May 30.

50 Kindt TJ, Goldsby RA, Osborne BA. Kuby Immunology. 6th ed. W.H. Freeman; 2007.

51 Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.

52 Harlow ED, Lane D. A laboratory manual. New York: Cold Spring Harbor Laboratory. 1988;579:44.

53 Leenaars M, Hendriksen CFM. Critical steps in the production of polyclonal and monoclonal antibodies. ILAR J. 2005;46(3):269–279.

54 Reichert JM. Monoclonal antibodies in the clinic. Nature biotechnology. 2001 Sep;19(9):819-22.

55 Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature reviews drug discovery. 2010 Oct;9(10):767-74.

56 Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nature reviews cancer. 2012 Apr;12(4):278-87.

57 Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. British journal of pharmacology. 2009 May;157(2):220-33.

58 Kaplon H, Reichert JM. Antibodies to watch in 2021. InMAbs 2021 Jan 1 (Vol. 13, No. 1, p. 1860476). Taylor & Francis.

59 Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1.

60 Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. InMAbs 2016 Oct 2 (Vol. 8, No. 7, pp. 1177-1194). Taylor & Francis.

61 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010 May;10(5):317-27.

62 Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nature reviews immunology. 2010 May;10(5):345-52.

Regular Issue Subscription Review Article
Volume 16
Issue 01
Received 01/04/2026
Accepted 01/04/2026
Published 04/04/2026
Publication Time 3 Days
70

Login


My IP

PlumX Metrics